Alpha-602

Alpha-602 is an investigational **biologic protein therapy** from Alpha Cognition being developed for **amyotrophic lateral sclerosis**. The program is based on **progranulin** biology, with development focused on **Granulin Epithelin Modules**, smaller polypeptide subunits derived from the larger progranulin protein. Progranulin is implicated in **cell survival, regulation of inflammatory processes, lysosomal homeostasis, and modulation of microglial responses to disease**, so Alpha-602 appears intended to restore or augment progranulin-driven neuroprotective and immunoregulatory signaling in neurodegeneration. Based on the provided information, the asset was granted **FDA Orphan Drug Designation** for ALS in March 2019 and remains in **preclinical development**, with work centered on identifying and validating an appropriate GEM formulation in animal models ahead of an FDA submission.

Other names

progranulinGranulin Epithelin ModulesGEMs